Breast Cancer Research and Treatment

, Volume 115, Issue 3, pp 651–659

Cyclin E deregulation is an early event in the development of breast cancer

  • Alexandra Shaye
  • Aysegul Sahin
  • Qiang Hao
  • Kelly Hunt
  • Khandan Keyomarsi
  • Isabelle Bedrosian
Report

DOI: 10.1007/s10549-008-0266-0

Cite this article as:
Shaye, A., Sahin, A., Hao, Q. et al. Breast Cancer Res Treat (2009) 115: 651. doi:10.1007/s10549-008-0266-0

Abstract

Cyclin E has been shown to be overexpressed in some human breast cancers, however, data to support deregulation of cyclin E as an early event in human mammary tumor development is lacking. We analyzed surgical specimens from 183 patients with breast carcinomas and evaluated cyclin E expression in areas of invasive carcinoma, adjacent carcinoma in situ (CIS), and non-neoplastic breast parenchyma. Overexpression of cyclin E was seen in one-third of invasive carcinoma samples, one-third of the CIS component and nearly half of the non-neoplastic breast epithelial cells adjacent to carcinoma (44% vs. 33%, P ≤ 0.05). Nuclear labeling for cyclin E was highly concordant between areas of in invasive carcinoma, CIS and non-neoplastic breast epithelial cells from the same patient (P < 0.0001). Localization of cyclin E to the cytoplasm was seen in a small proportion of tumor samples. Our findings suggest that cyclin E deregulation is an early event in the progression from histologically benign mammary epithelial cells to invasive carcinoma and occurs through both overexpression and altered cellular localization.

Keywords

Cyclin EPremalignant breast diseaseBreast cancerCytoplasmic localization

Copyright information

© Springer Science+Business Media, LLC. 2008

Authors and Affiliations

  • Alexandra Shaye
    • 1
  • Aysegul Sahin
    • 1
  • Qiang Hao
    • 2
  • Kelly Hunt
    • 2
    • 3
  • Khandan Keyomarsi
    • 2
    • 3
  • Isabelle Bedrosian
    • 2
  1. 1.Department of PathologyUniversity of Texas, M.D. Anderson Cancer CenterHoustonUSA
  2. 2.Department of Surgical OncologyUniversity of Texas, M.D. Anderson Cancer CenterHoustonUSA
  3. 3.Department of Experimental Radiation OncologyUniversity of Texas, M.D. Anderson Cancer CenterHoustonUSA